The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As mentioned before definately worth a tweet
The conclusion of Boil B's post www.nature.com/articles/s41375-021-01266-6 is yet another huge validation of Sareum and its science. You can't get better than "we found a potential role for JAK-inhibitors in reducing the risk of death in persons with COVID-19". As I said on Wednesday I really do feel that we could be about to experience a 2020 Synairgen moment, of 6p to 240p in the space of just a few months, with our own share price. FOMO will kick in shortly. Thanks Boil B for the post by the way. Keep them coming everyone.
Potnak.....that is the problem any company making a offer has.....make offer now of 30p or leave and wait for data to come out and it says wow.......then the market 3I'll decide the price not the pharna company.....if it goes to 50p on anazibf data, you dont think Sareum will sell for 30p.....all risk and reward and missing out and someone else getting it. I would say 50p tonight is dirt cheap for any big pharma...or wait and see 38000 percent increase like a small Canadian drug did on a covid19 drug......
It's all about the science baby......just science!!!! The rest the market will take care of!!!
Bang on Thoth. I can even start to explain how big Tyk2 1802 cancer is- no tox no mtd, worldwide patents and no competition in the cancer tyk2 marketplace and we are almost phase1 ready- some perspective, unbelievably unique position to be in and groundbreaking transformational gangbusting if it goes to ph1 which at this point looks very likely as IP is sorted. John Reader your a genius and patenting up 1802 was the master stroke of the century.
Do you not think we'll get a relatively low ball offer, Thoth? I just don't think we'll be allowed to go as far as a pound. I know RMM said he'd wait until June to get his calculator out but I think a TO is coming but at what price?
Its going to be hard to choose. Looks like covid will get free grant funding all the way. Immune we await pfizer readout shortly to see if tyk2/jak1 is superior. Tyk2 cancer is bigger than many think and relatively cheap to trial. Chk1 srra need to domething in short order or risk giving it back. Several buses arriving shortly. I think a quid quite achievable if they land. Gla
Potnak.....good post. If you make our tyk2 molecule for covid19 a separate respiratory patent that would resolve that. The longer you leave a ***** in heat out there, the more dogs it attracts. Of all sizes ....
If covid19 in humans a go can see this above 10p and if successful data then a £1 as be amazing, as show it works and safe and can be further used in sepsis a massive market and other respiratory conditions.
Still not worked out chk1 or tyk2 autoimmune and tyk2 cancer... 28p thoth prediction that was laughed out,and even inthen thought impossible...looks cheap as chips
If you use the same percentage gain that's a 40 bagger. What are people's thoughts on potential deals? I think that 1801 for covid will have made making a deal much more complicated. As I understand it. We wouldn't be able to on license 1801 Covid without the Licensor getting 1801 immune as well. That is unless the secret patent is for covid and we will have a new compound, 1803 for respiratory diseases? With this in mind, I still think we may get a TO offer come in. We are in the risk-reward sweet spot for both parties.
The ball clearly lies in the interested party or parties. They can make offers. Sareum can sit back and wait for result of trial. There is almost no chance of a CTA not being approved. I would think most of this has and is being resolved in the background. I dare say offers have been made
If we show positive fir XY and Z we will get this. If we can treat Covid then add another nought on the end.
Will be a nightmare for Tim working all them milestone payments out. But, better than that should it work,will be the end of so much suffering and death to the world of the old, not so old and little children That you can not put a price on!
Regards
This is patently a game changing moment for Sareum with the report disclosing that the results establish TYK2 as a potential therapeutic agent for the treatment of autoimmune diseases and severe COVID-19. It doesn’t get much better than that in our sector currently. It feels to me that we could be about to experience a 2020 Synairgen moment (6p to 240p in the space of just a few months) with our own share price, on the back of this incredible data. Surely now Stephen Parker, John Reader and Tim Mitchell, with the help of Dr Owen in particular, will be able to secure the mother of all deals imminently with a worldwide pharma company.